Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tien Liang BioTech Co (4127) Fair Value & Analysis

Healthcare · TW · Market cap 3.1B TWD

Price64.00 TWD
Fair Value31.08 TWD
Upside-51.4%
Quality95/100
Evidence: Low Range 23.31 TWD – 38.85 TWD

Fair value as of: Jun 24, 2026

Analysis

Tien Liang BioTech Co (4127) currently trades at 64.00 TWD, while our model-based Fair Value estimate is 31.08 TWD — implying the stock looks roughly 51.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese and Western medicine, other healthcare, and cosmetic products through online and offline channels. Tien Liang BioTech Co., Ltd. was founded in 1971 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Tien Liang BioTech Co (4127) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 31.08 TWD versus a price of 64.00 TWD — about −51% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4127?
Our 21-model fair value for Tien Liang BioTech Co is 31.08 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 64.00 TWD.
What is the quality score of 4127?
Tien Liang BioTech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.